Exploring Low-Dose Naltrexone as a Potential Treatment for Long COVID
Research from Griffith University suggests that low-dose naltrexone, a drug used for opioid addiction, may be an effective treatment for Long COVID by restoring cellular function and improving symptoms.
Recent research from Griffith University has indicated that low-dose naltrexone (LDN), a medication traditionally used for opioid addiction, may offer new hope in the fight against Long COVID. A study published in Frontiers in Molecular Biosciences demonstrated that LDN successfully restored cellular function in human cells affected by Long COVID.
Long COVID, affecting over 77 million people worldwide, causes persistent symptoms such as fatigue, neurological issues, and immune dysfunction long after the initial infection resolves. The study’s lead researcher, Professor Sonya Marshall-Gradisnik of Griffith’s National Center for Neuroimmunology and Emerging Diseases (NCNED), emphasized the urgency for effective treatments, and highlighted that LDN is a safe, repurposed drug.
The team’s prior investigations revealed that TRPM3 ion channels, which facilitate calcium transport into cells and are vital for cellular signaling, are faulty in Long COVID patients. Ph.D. candidate Etianne Sasso explained that these defective ion channels can be likened to malfunctioning doors in a house, preventing essential calcium entry. This impairment hampers various bodily functions, including immune responses and neurological activity.
The study demonstrated that low-dose naltrexone effectively fixes these dysfunctional 'doors,' enabling proper opening and closing of ion channels. Since these channels influence key processes such as immune response and pain regulation, restoring their function could significantly alleviate Long COVID symptoms. Currently, NCNED is conducting clinical trials to evaluate LDN’s effectiveness in improving symptoms, disability, and quality of life among Long COVID patients.
This promising discovery offers a new avenue for treating a condition that has been challenging to manage and highlights the potential of drug repurposing in medical research.
Source: https://medicalxpress.com/news/2025-05-drug-typically-opioid-addiction-covid.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Hormel Recalls Over 256,000 Pounds of Canned Beef Stew Due to Contamination Concerns
Hormel Foods has recalled over 256,000 pounds of canned beef stew due to reports of wood fragments in the product. Consumers are advised to dispose of or return affected cans to prevent potential health risks.
New Insights into How Human Eggs Maintain Longevity Could Improve IVF Outcomes
New research reveals that human eggs minimize cellular waste activity during maturation, a strategy that may enhance their longevity and improve IVF success rates. Discover how this minimalist approach to cellular maintenance can influence fertility treatments.
Innovative Surgical Technique Shows Promise for Treating Groin Hernias in Women
A new surgical method evaluated in Uganda offers a promising, accessible treatment for groin hernias in women, including high-risk femoral hernias, with potential applications worldwide.
New Insights into Immune Mechanisms Preventing Neurological Damage from Oropouche Virus
New research uncovers how the immune system's early response, particularly B cells and MyD88 protein, prevents neurological damage from Oropouche virus, offering hope for future therapies. Read about the latest findings that could aid in developing vaccines and treatments.